The main result of the current study is that serum levels of BACE1 are increased (higher than 60%) in AD and MCI-AD in comparison with healthy controls and that a cut-off of 11.04 kU/L can discriminate patients with a high sensitivity (98.31%) and specificity (100%). This evidence concerns the gene BACE1 and Alzheimer disease.